Raymond J. Lim

796 total citations
17 papers, 518 citations indexed

About

Raymond J. Lim is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Raymond J. Lim has authored 17 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Raymond J. Lim's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (8 papers) and CAR-T cell therapy research (3 papers). Raymond J. Lim is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (8 papers) and CAR-T cell therapy research (3 papers). Raymond J. Lim collaborates with scholars based in United States, United Kingdom and China. Raymond J. Lim's co-authors include Lomon So, Pingda Ren, Michelle M. Lilly, Matthew R. Janes, S. Tiong Ong, Marina Konopleva, Sharmila Mallya, Michael Martin, Jose J. Limon and Jing Chen and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Raymond J. Lim

15 papers receiving 515 citations

Peers

Countries citing papers authored by Raymond J. Lim

Since Specialization

Citations

This map shows the geographic impact of Raymond J. Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond J. Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond J. Lim more than expected).

Fields of papers citing papers by Raymond J. Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond J. Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond J. Lim. The network helps show where Raymond J. Lim may publish in the future.

Co-authorship network of co-authors of Raymond J. Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond J. Lim. A scholar is included among the top collaborators of Raymond J. Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond J. Lim. Raymond J. Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Characteristics of a CCL21 Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer 2024 ·Molecular Cancer Therapeutics ·Michael S. Oh, Camelia Dumitras, Ramin Salehi‐Rad, Linh M. Tran, Kostyantyn Krysan, Raymond J. Lim, (unknown), (unknown), Aaron Lisberg, Edward B. Garon, Steven M. Dubinett, Bin Liu	6
2	Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction 2024 ·Journal of Thoracic Oncology ·Xin Zhao, Bin Liu, William N. William, Kaloyan M. Tsanov, Yu-Jui Ho, Francisco M. Barriga, Raymond J. Lim, (unknown), (unknown), Yushen Du, Scott W. Lowe, Steven M. Dubinett, Teresa Davoli, Scott M. Lippman	3
3	CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer 2024 ·Cell Reports Medicine ·Raymond J. Lim, Ramin Salehi‐Rad, Linh M. Tran, Michael S. Oh, Camelia Dumitras, (unknown), Rui Li, (unknown), (unknown), (unknown), (unknown), (unknown), Stephanie L. Ong, Kostyantyn Krysan, Steven M. Dubinett, Bin Liu	46
4	Multi-organ landscape of therapy-resistant melanoma 2023 ·Nature Medicine ·Sixue Liu, (unknown), Shirley H. Lomeli, Yan Wang, Xiao Zhang, Zhentao Yang, Raymond J. Lim, Camelia Dumitras, Philip O. Scumpia, (unknown), Gatien Moriceau, Douglas B. Johnson, Stergios J. Moschos, Roger S. Lo	20
5	Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma 2023 ·Signal Transduction and Targeted Therapy ·Junhui Hu, Ping Tan, (unknown), Nicholas Bayley, Shiruyeh Schokrpur, (unknown), Yangjun Zhang, Raymond J. Lim, Camelia Dumitras, Lu Yang, Steven M. Dubinett, Parmjit Jat, Jacques Van Snick, Jiaoti Huang, Arnold I. Chin, Robert M. Prins, Thomas G. Graeber, Hua Xu, Lily Wu	40
6	Immunotherapy: OMNI-CAR, A UNIVERSAL CAR T CELL THERAPY UTILIZING COVALENT SPYTAG/SPYCATCHER BINDING TO TARGET MULTIPLE ANTIGENS IN DIFFERENT TUMORS 2023 ·Cytotherapy ·(unknown), (unknown), Junming Tong, Raymond J. Lim, (unknown), Phillip K. Darcy	0
7	Abstract 4208: In situ vaccination of non-small cell lung cancer with CXCL9/10-engineered dendritic cells combined with PD-1 blockade 2022 ·Cancer Research ·Raymond J. Lim, Ramin Salehi‐Rad, Linh M. Tran, Camelia Dumitras, (unknown), (unknown), (unknown), (unknown), Rui Li, Kostyantyn Krysan, Bin Liu, Steven M. Dubinett	1
8	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non–Small Cell Lung Cancer 2021 ·Cancer Research ·Rui Li, Ramin Salehi‐Rad, (unknown), Milica Momcilovic, Raymond J. Lim, Stephanie L. Ong, (unknown), (unknown), (unknown), Camelia Dumitras, Zhe Jing, Stacy J. Park, Kostyantyn Krysan, David B. Shackelford, Linh M. Tran, Bin Liu, Steven M. Dubinett	64
9	Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer 2021 ·Cancers ·(unknown), (unknown), Linh M. Tran, Raymond J. Lim, Camelia Dumitras, Tristan Grogan, David Elashoff, Ramin Salehi‐Rad, Steven M. Dubinett, Bin Liu, Claudio Scafoglio	5
10	Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden 2021 ·Cancer Immunology Immunotherapy ·Ramin Salehi‐Rad, Rui Li, Linh M. Tran, Raymond J. Lim, (unknown), Milica Momcilovic, Stacy J. Park, Stephanie L. Ong, Maryam Shabihkhani, (unknown), Manash K. Paul, David B. Shackelford, Kostyantyn Krysan, Bin Liu, Steven M. Dubinett	15
11	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma 2021 ·Cell Reports Medicine ·Sixue Liu, Hannah M. Knochelmann, Shirley H. Lomeli, Aayoung Hong, Mary S. Richardson, Zhentao Yang, Raymond J. Lim, Yan Wang, Camelia Dumitras, Kostyantyn Krysan, Cynthia Timmers, Martin J. Romeo, Carsten Krieg, Elizabeth C. O’Quinn, Joshua D. Horton, (unknown), Chrystal M. Paulos, David M. Neskey, Roger S. Lo	31
12	Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC. 2021 ·Journal of Clinical Oncology ·Aaron Lisberg, Bin Liu, Ramin Salehi‐Rad, Jay M. Lee, Linh M. Tran, Kostyantyn Krysan, Raymond J. Lim, Camelia Dumitras, (unknown), Fereidoun Abtin, Robert D. Suh, Scott Genshaft, Gregory A. Fishbein, Anita Kaul, Kanwarpal Kahlon, (unknown), Jonathan W. Goldman, David Elashoff, Edward B. Garon, Steven M. Dubinett	2
13	A11 Blockade of Myeloid Suppressor Cells Overcomes the Anti-PD-1/PD-L1 Resistance in KRAS-Driven and LKB1-Deficient NSCLC 2020 ·Journal of Thoracic Oncology ·(unknown), Ramin Salehi‐Rad, Milica Momcilovic, Raymond J. Lim, (unknown), Ziling Huang, Linh M. Tran, (unknown), Manash K. Paul, Michael A. Teitell, John D. Minna, Kostyantyn Krysan, David B. Shackelford, (unknown), Steven M. Dubinett	0
14	Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy 2020 ·Open Forum Infectious Diseases ·K. Schwab, Sepehr Hamidi, (unknown), Raymond J. Lim, Négar Khanlou, (unknown), Camelia Dumitras, (unknown), (unknown), Tisha S. Wang, Rajan Saggar, Jeffrey A. Goldstein, John A. Belperio, Steven M. Dubinett, Jocelyn T. Kim, Ramin Salehi‐Rad	6
15	Abstract 2710: Depletion of CXCR2-dependent myeloid-derived suppressor cells (MDSCs) overcomes anti-PD-1 resistance in a murine model of LKB1-deficient non-small cell lung cancer (NSCLC) with high mutational load 2019 ·Cancer Research ·Rui Li, Ramin Salehi‐Rad, Stephanie L. Ong, Milica Momcilovic, Bin Liu, Raymond J. Lim, Linh M. Tran, Ziling Huang, Zhe Jing, Manash K. Paul, Kostyantyn Krysan, Stacy Park, John D. Minna, Michael A. Teitell, David B. Shackelford, Steven M. Dubinett	1
16	Intratumoral CCL21-Gene Modified Dendritic Cells (CCL21-DC) Combined with Checkpoint Blockade in Murine Models of Non-Small Cell Lung Cancer (NSCLC) with Varying Mutational Load 2019 ·Ramin Salehi‐Rad, R. Li, (unknown), Raymond J. Lim, Linh M. Tran, (unknown), (unknown), Manash K. Paul, Kostyantyn Krysan, David B. Shackelford, Steven M. Dubinett	2
17	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor 2010 ·Nature Medicine ·Matthew R. Janes, Jose J. Limon, Lomon So, Jing Chen, Raymond J. Lim, (unknown), (unknown), Michelle M. Lilly, Sharmila Mallya, S. Tiong Ong, Marina Konopleva, Michael Martin, Pingda Ren, Yi Liu, Christian Rommel, (unknown)	276

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact